Pfizer's Blockbuster Hopeful Can't Win in Europe

Pfizer investors have cheered the stock's remarkable gains this year, but the company's performance in the shadow of major patent expirations has been remarkable. New drugs have risen to supplant the firm's old blockbusters, and rheumatoid arthritis drug Xeljanz, approved by the Food and Drug Administration last year, has led the charge as one of tomorrow's most promising therapies.

Unfortunately, European regulators didn't feel the same way. Late last week, Europe's Committee for Medicinal Products for Human Use, or CHMP, recommended that Xeljanz not be approved to treat rheumatoid arthritis across the Atlantic. Should you be worried about Xeljanz's failure in Europe? Motley Fool contributor Dan Carroll and health care analyst Max Macaluso tell you what you need to know in the video below.

Pfizer missed a chance to capture of Europe's rheumatoid arthritis market with Xeljanz, but it's still looking up to the biggest immunology drug on the market: AbbVie's Humira. However, is AbbVie safe, with this blockbuster making up a huge portion of its total sales? The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.

The article Pfizer's Blockbuster Hopeful Can't Win in Europe originally appeared on Fool.com.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.